PL3956310T3 - <div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div> - Google Patents
<div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div>Info
- Publication number
- PL3956310T3 PL3956310T3 PL20734624.8T PL20734624T PL3956310T3 PL 3956310 T3 PL3956310 T3 PL 3956310T3 PL 20734624 T PL20734624 T PL 20734624T PL 3956310 T3 PL3956310 T3 PL 3956310T3
- Authority
- PL
- Poland
- Prior art keywords
- div
- treatment
- amino acid
- acid derivatives
- modified amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL429656A PL240297B1 (pl) | 2019-04-16 | 2019-04-16 | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
| PCT/PL2020/050028 WO2020214043A1 (en) | 2019-04-16 | 2020-04-16 | Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3956310T3 true PL3956310T3 (pl) | 2026-02-16 |
Family
ID=71138777
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL429656A PL240297B1 (pl) | 2019-04-16 | 2019-04-16 | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
| PL20734624.8T PL3956310T3 (pl) | 2019-04-16 | 2020-04-16 | <div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div> |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL429656A PL240297B1 (pl) | 2019-04-16 | 2019-04-16 | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US12421189B2 (pl) |
| EP (2) | EP3956310B1 (pl) |
| CN (1) | CN113767088A (pl) |
| DK (1) | DK3956310T3 (pl) |
| ES (1) | ES3051032T3 (pl) |
| FI (1) | FI3956310T3 (pl) |
| HU (1) | HUE073599T2 (pl) |
| PL (2) | PL240297B1 (pl) |
| WO (1) | WO2020214043A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL240297B1 (pl) | 2019-04-16 | 2022-03-14 | Univ Jagiellonski | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
| PL243119B1 (pl) * | 2020-04-16 | 2023-06-26 | Univ Jagiellonski | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych |
| PL244897B1 (pl) * | 2021-11-24 | 2024-03-25 | Univ Jagiellonski | Deuterowane funkcjonalizowane pochodne α-alaniny, zwłaszcza do leczenia chorób neurologicznych |
| CN116735761A (zh) * | 2023-08-16 | 2023-09-12 | 四川省药品检验研究院(四川省医疗器械检测中心) | 一种人血浆中布立西坦的uplc-ms/ms检测方法 |
| KR20260100334A (ko) * | 2023-10-20 | 2026-06-29 | 알타이 테라퓨틱스, 인크. | 신경근육 장애 등의 치료를 위한 dux4 억제제로서의 n-페닐-3-(2,5-디옥소피롤리딘-1-일)프로판아미드 유도체 및 유사 화합물 |
| PL450241A1 (pl) * | 2024-11-12 | 2026-05-18 | Uniwersytet Jagielloński | Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu |
| WO2026150001A1 (en) | 2025-01-09 | 2026-07-16 | Iqure Pharma Inc. | Positive allosteric modulator (pam) of the eaat2/glt-1 glutamate transporter for use in the treatment or prevention of dravet syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL240297B1 (pl) | 2019-04-16 | 2022-03-14 | Univ Jagiellonski | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
| PL243119B1 (pl) | 2020-04-16 | 2023-06-26 | Univ Jagiellonski | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych |
-
2019
- 2019-04-16 PL PL429656A patent/PL240297B1/pl unknown
-
2020
- 2020-04-16 US US17/593,974 patent/US12421189B2/en active Active
- 2020-04-16 PL PL20734624.8T patent/PL3956310T3/pl unknown
- 2020-04-16 EP EP20734624.8A patent/EP3956310B1/en active Active
- 2020-04-16 DK DK20734624.8T patent/DK3956310T3/da active
- 2020-04-16 EP EP25188793.1A patent/EP4623910A3/en active Pending
- 2020-04-16 HU HUE20734624A patent/HUE073599T2/hu unknown
- 2020-04-16 CN CN202080028935.4A patent/CN113767088A/zh active Pending
- 2020-04-16 WO PCT/PL2020/050028 patent/WO2020214043A1/en not_active Ceased
- 2020-04-16 ES ES20734624T patent/ES3051032T3/es active Active
- 2020-04-16 FI FIEP20734624.8T patent/FI3956310T3/fi active
-
2024
- 2024-09-30 US US18/901,530 patent/US12331019B2/en active Active
-
2025
- 2025-08-18 US US19/302,954 patent/US20250382265A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3956310B1 (en) | 2025-08-06 |
| EP4623910A2 (en) | 2025-10-01 |
| US12331019B2 (en) | 2025-06-17 |
| HUE073599T2 (hu) | 2026-01-28 |
| US20250026717A1 (en) | 2025-01-23 |
| CN113767088A (zh) | 2021-12-07 |
| EP4623910A3 (en) | 2025-12-10 |
| US12421189B2 (en) | 2025-09-23 |
| US20250382265A1 (en) | 2025-12-18 |
| US20220153694A1 (en) | 2022-05-19 |
| WO2020214043A1 (en) | 2020-10-22 |
| DK3956310T3 (da) | 2025-10-27 |
| PL240297B1 (pl) | 2022-03-14 |
| ES3051032T3 (en) | 2025-12-23 |
| EP3956310A1 (en) | 2022-02-23 |
| PL429656A1 (pl) | 2020-10-19 |
| FI3956310T3 (fi) | 2025-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288214A (en) | Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders | |
| ZA202212876B (en) | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders | |
| IL280710A (en) | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy | |
| EA201891374A1 (ru) | Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение | |
| EP4640277A3 (en) | C21-N-PYRAZOLYL STEROID WITH C3,3-19-NOR DISUBSTITUTION FOR THERAPEUTIC USE | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| PA8780101A1 (es) | Imidazopiridazina y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
| HUE073599T2 (hu) | Módosított aminosav-származékok neurológiai betegségek és kiválasztott pszichiátriai rendellenességek kezelésére | |
| PL3405215T3 (pl) | Sposoby leczenia choroby danona i innych zaburzeń autofagii | |
| UY30097A1 (es) | Usos terapeuticos de inhibidores de rtp801 | |
| IL286268A (en) | Pridopidine for use in the treatment of mitochondrial associated diseases and disorders, including symptoms thereof | |
| SMT202400486T1 (it) | Proteine di capside avv modificate per il trattamento della malattia artritica | |
| EP4380588A4 (en) | PSYCHOACTIVE DRUGS AND THEIR USE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS AND PSYCHIATRIC AND NEUROLOGICAL DISORDERS | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| IL287748A (en) | Treatment and detection of inherited neuropathies and associated disorders | |
| EP3581175A4 (en) | PREPARATION FOR THE ADMINISTRATION OF A DRUG FOR THE TREATMENT OF MENTAL ILLNESSES OR CENTRAL NERVOUS SYSTEM DISORDERS | |
| EP3649256A4 (en) | METHOD OF TREATMENT INFLAMMATION AND RELATED DISEASES AND DISEASES BY INHIBITION OF ALPHA-PROTEIN KINASE 1 | |
| DOP2022000093A (es) | Inhibidores de adrenoreceptor adrac2 | |
| IL310870A (en) | Quinazoline compounds for treatment of disease | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| EP4058017A4 (en) | MEDICINAL FORMULATIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| EP3488850A4 (en) | NEW APPLICATION OF GZD824 IN THE TREATMENT OF LYMPHOBLASTIC LEUKEMIA. | |
| PL4135840T3 (pl) | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych | |
| EP4410296A4 (en) | DIRECT TRANSDIFFERENTIATION FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| KR20240099184A9 (ko) | 재생불량성 질환 치료를 위한 mrna 레귤론 요법 |